ASCO: SWOG Trials Have Had Considerable Impact on Cancer

Share this content:
ASCO: SWOG Trials Have Had Considerable Impact on Cancer
ASCO: SWOG Trials Have Had Considerable Impact on Cancer

TUESDAY, June 6, 2017 (HealthDay News) -- Over the past 60 years, SWOG treatment trials have had a considerable impact on patients with cancer, according to a study published online June 5 in JAMA Oncology to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.

Joseph M. Unger, Ph.D., from the SWOG Statistical Center in Seattle, and colleagues used data from all treatment trials during SWOG's history (1956 to 2016) to examine the extent to which positive National Cancer Institute (NCI)-sponsored cancer treatment trials had benefited patients with cancer in the U.S. population. Data were included from 23 positive SWOG treatment trials from a variety of disease settings.

A total of 12,361 patients were enrolled in the 23 positive trials. The researchers estimated that through 2015, 3.34 million life-years were gained from these 23 trials. Under most model simulations, estimates were greater than 2 million life-years gained. Per life-year gained, the U.S. dollar return on investment was $125.

"The NCI's investment in its cancer cooperative group research program has provided exceptional value and benefit to the American public through its research programs generating positive cancer treatment trials," the authors write.

Abstract/Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Even Overdose Doesn't Stop Opioid Prescribing

Even Overdose Doesn't Stop Opioid Prescribing

Few receive medication-assisted treatment after hospital discharge, researchers find

NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

No improvement in clinical outcomes versus usual care in heart failure and reduced ejection fraction

Oral Corticosteroids No Benefit for LRI in Non-Asthmatic Adults

Oral Corticosteroids No Benefit for LRI in Non-Asthmatic ...

No decrease in cough duration, severity for adults without asthma with lower respiratory tract symptom

is free, fast, and customized just for you!

Already a member?

Sign In Now »